Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

This summer, Geron Corporation of Menlo Park, California, will begin treating ten patients who have suffered a complete thoracic-level spinal cord injury in a phase 1 multicenter trial.

Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...